| Gene symbol | GRB2 | Synonyms | ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | growth factor receptor bound protein 2 | ||||
| GTO ID | GTC1649 |
| Trial ID | NCT02923986 |
| Disease | Leukemia | Myelodysplastic Syndrome |
| Altered gene | GRB2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | BP1001|Liposomal Grb2 Antisense Oligonucleotide|Liposomal Grb-2|L-Grb-2 |
| Co-treatment | Dasatinib |
| Phase | Phase1|Phase2 |
| Recruitment status | Withdrawn |
| Title | A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Including Chronic Phase Patients Who Have Failed Initial Tyrosine Kinase Inhibitor (TKI) Therapy, Accelerated or Blast Phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS) |
| Year | 2016 |
| Country | United States |
| Company sponsor | Bio-Path Holdings, Inc. |
| Other ID(s) | BP1001-202-CML |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||